Abbott Laboratories

  • Earnings Score
  • Moat Score
  • Safety Score
  • Final Score
  • Market Cap $199.84B
  • PE 35
  • Debt $14.98B
  • Cash $7.56B
  • EV $207.26B
  • FCF $6.49B

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$5.74B
EBIT$6.78B
ROE14%
ROA9%
FCF$6.49B
Equity$40.03B
Growth Stability17%
PE34.79
PEG3.45
PB4.99
P/FCF30.81
P/S4.85
Price/Cash0.04
Debt/Equity0.37
Debt/FCF2.31
Net Margins13%
Gross Margins56%
Op. Margins16%
Earnings CAGR24%
Sales Growth YoY5%
Sales Growth QoQ2%
Sales CAGR10%
FCF CAGR17%
Equity CAGR7%
Earnings Stability0.53
Earnings Growth YoY15%
Earnings Growth QoQ26%
Earnings CAGR 5Y10%
Sales CAGR 5Y6%
FCF CAGR 5Y2%
Equity CAGR 5Y6%
Earnings CAGR 3Y-4%
Sales CAGR 3Y-4%
FCF CAGR 3Y-19%
Equity CAGR 3Y4%
Market Cap$199.84B
Revenue$41.22B
Dividend Yield2%
Payout Ratio66%
Assets$74.36B
Total Debt$14.98B
Cash$7.56B
Shares Outstanding1.73B
EV207.26B
Earnings Score81%
Moat Score92%
Safety Score63%
Final Score79%
Working Capital8.9B
Current Ratio1.6
Shares Growth 3y-1%
Equity Growth QoQ1%
Equity Growth YoY6%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

SEC Filings

Direct access to Abbott Laboratories (ABT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Abbott Laboratories compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Abbott Laboratories compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 24%
Stability 53%
loading chart...

Abbott Laboratories Discounted Cash Flow

Fully customizable DCF calculator online for Abbott Laboratories.

= $208B
012345678910TV
fcf$6.5B$7.6B$8.8B$10B$12B$14B$16B$19B$22B$26B$30B$303B
DCF$6.9B$7.3B$7.7B$8.2B$8.7B$9.2B$9.8B$10B$11B$12B$117B
Value$208B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins11%22%7%2%8%11%13%16%16%14%13%
ROA-8%6%3%5%7%7%11%11%9%9%
ROE-21%7%2%8%12%14%20%19%15%14%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF-5.5811.986.363.994.273.282.172.443.122.31
Debt over Equity0.360.421.060.910.640.610.570.520.520.410.37
Growth Stability---17%100%100%100%100%100%93%17%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth-1%2%31%12%4%8%24%1%-8%6%
Earnings YoY growth-94%-68%-66%403%56%22%57%-2%-17%10%
Equity YoY growth--1%-3%50%-1%2%5%9%2%5%6%
FCF YoY growth--200%14%141%11%-8%27%51%-10%-35%2%